WATCH: FDA panel approves Moderna, Pfizer Covid-19 vaccines for children under five

The US Food and Drug Administration (FDA) panel of 21 medical experts has unanimously approved the use of Moderna and Pfizer-BioNTech Covid-19 vaccines on children aged 6 months to 5 years.

While the Moderna vaccine is administered in two separate doses for children aged from six months to five years, the Pfizer vaccine will be administered in a three-dose course for children from six months to four years of age. Picture: Courtney Africa/African News Agency (ANA) Archives

The US Food and Drug Administration (FDA) panel of 21 medical experts has unanimously approved the use of Moderna and Pfizer-BioNTech Covid-19 vaccines on children aged 6 months to 5 years.

Cape Town – The US Food and Drug Administration (FDA) panel of 21 medical experts has unanimously approved the use of Moderna and Pfizer-BioNTech Covid-19 vaccines on children aged 6 months to 5 years.

According to Sputnik news agency, the panel’s conclusion is expected to expedite the FDA’s authorisation of the two Covid-19 vaccines for use on babies more than six months old and young children up to age five across the US.

While the Moderna vaccine is administered in two separate doses for children aged from six months to five years, the Pfizer vaccine will be administered in a three-dose course for children from six months to four years of age.

CNBC reported that the data collected by the Centers for Disease Control and Prevention (CDC) shows that the risk of death for children from Covid-19 is much lower than that of the common flu and that health-care providers will probably get the green light to start administering shots shortly after FDA authorisation.

Meanwhile, the Guardian reported that people who caught Covid-19 in the first wave get no boost to their immune response if they happen to catch Omicron.

Following a study of triple-vaccinated people, experts say that infections can affect their immune response.

IOL

ANA NEWS WIRE Disclaimer:
The African News Agency (ANA) is a news wire service and therefore subscribes to the highest standards of journalism as it relates to accuracy, fairness and impartiality.
ANA strives to provide accurate, well sourced and reliable information across Text, Images and Video. Where errors do appear, ANA will seek to correct these timeously and transparently.
The ANA platform also contains news and information from third party sources. ANA has sought to procure reliable content from trusted news sources but cannot be held responsible for the accuracy and opinions provided by such sources on the ANA platform or linked sites.
The content provided for on the ANA News Wire platform, both through the ANA news operation and via its third party sources, are for the sole use of authorised subscribers and partners. Unauthorised access to and usage of ANA content will be subject to legal steps. ANA reserves its rights in this regard.
ANA makes every effort to ensure that the website is up and running smoothly at all times, however ANA does not take responsibility for, and will not be held liable for times when the website is temporarily unavailable due to technical issues that are beyond our control.